Clinical review: Breast development in trans women receiving cross-sex hormones

Journal of Sexual Medicine

Volumn 11, Issue 5, 2014, Pages 1240-1247

  Wierckx, Katrien ^a   Gooren, Louis ^b   T'Sjoen, Guy ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b AndroConsult   (Thailand)

Author keywords

Breast; Breast cancer; Progesterone; Side effects; Transsexualism

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; PROGESTERONE; TESTOSTERONE;

AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BREAST AUGMENTATION; BREAST CIRCUMFERENCE; BREAST DEVELOPMENT; BREAST SIZE; CHEST CIRCUMFERENCE; CROSS SEX HORMONE THERAPY; ESTRADIOL BLOOD LEVEL; FEMINIZATION; HORMONAL THERAPY; HUMAN; MALE; MALE TO FEMALE TRANSSEXUAL; ORGAN SIZE; PRIORITY JOURNAL; PUBERTY; SYSTEMATIC REVIEW; TREATMENT DURATION;

BREAST; BREAST CANCER; PROGESTERONE; SIDE EFFECTS; TRANSSEXUALISM;

ADULT; BREAST; GONADAL STEROID HORMONES; HUMANS; MALE; PROGESTINS; TRANSSEXUALISM;

EID: 84899486488     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12487     Document Type: Article

References (62)

1. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-3154.
2. Marshall WA, Tanner TJ. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
3. Lanari C, Molinilo MA. Progesterone receptors-animal models and cell signaling in breast cancer: diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res 2002;4:240-243.
4. Russo J, Santen SR, Russo IR. Hormonal control of breast development. In: De Groot LJ, Jameson JL, eds. Endocrinology, adult and pediatric. Philadelphia: Saunders; 2010.
5. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003;88:3467-3473.
6. Tangpricha V, Ducharme SH, Barber TW, Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocr Pract 2003;9:12-21.
7. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
8. Gooren LJ. Clinical practice: care of transsexual persons. N Engl J Med 2011;364:1251-1257.
9. Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T'Sjoen G. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012;9:2641-2651.
10. Levy J, Burshell A, Marbach M, Afllalo L, Glick SM. Interaction of spironolactone with oestradiol receptors in cytosol. J Endocrinol 1980;84:371-379.
11. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin M, Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285:29932-29940.
12. Mueller A, Binder H, Cupisti S, Hoffmabb I, Beckmann MW, Dittirch R. Effects on the male Endocrine system of long-term treatment with Gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals. Horm Metab Res 2006;38:183-187.
13. Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire S, Barret J. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab 2012;97:4422-4428.
14. Oriel KA. Medical care of transsexual patients. J Gay Lesbian Med Assoc 2000;4:185-194.
15. Orentreich N, Durr N. Mammogenesis in transsexuals. J Invest Dermatol 1974;63:142-146.
16. Meyer WJ III, Jordan W, Finkelstein JW, Stuart C, Webb A, Smith E, Payer A, Walker P. Physical and hormonal evaluation of transsexual patients during hormonal therapy. Arch Sex Behav 1981;10:347-356.
17. Meyer WJ III, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Arch Sex Behav 1986;15:121-138.
18. Prior JC, Vigna Y, Watson D. Sprionolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav 1989;18:49-57.
19. Reutrakul S, Ongphiphadhanakul B, Piaseu N, Krittiyawong S, Chanprasertyothin S, Bunnag P, Rajatanavin R. The effects of oestrogen exposure on bone mass in male to female transsexuals. Clin Endocrinol (Oxf) 1998;49:811-814.
20. Kanhai R, Hage J, Mulder J. Long-term outcome of augmentation mammaplasty in male-to-female transsexuals: a questionnaire survey of 107 patients. Br J Plast Surg 2000;53:209-211.
21. Kanhai R, Hage J, Karim R. Augmentation mammaplasty in male-to-female trans-sexuals: facts and figures from Amsterdam. Scand J Plast Reconstr Surg Hand Surg 2001;35:203-206.
22. Dittrich R, Binder H, Cupisti Sn Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using Gonadotropin-Releasing Hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-592.
23. De Cuypere G, T'Sjoen G, Beerten R, Selvaggi G, De Sutter P, Hoebeke P, Monstrey S, Vansteenwegen A, Rubens R. Sexual and physical health after sex reassignment surgery. Arch Sex Behav 2005;34:679-690.
24. Sosa M, Jódar E, Arbelo E, Domínguez C, Saavedra P, Torres A, Salido E, Limiñana JM, Gómez De Tejada MJ, Hernández D. Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. Eur J Intern Med 2004;15:231-237.
25. Wallace PM, Rasmussen S. Analysis of Adulterated Silicone: implications for health promotion. Int J Transgenderism 2010;12:167-175.
26. Chen M, Yalamanchili C, Hamous J, Piskun MA, Weis B. Acute inflammatory response of the male breasts secondary to self-injection of petroleum jelly: a case report. South Med J 2008;101:422-424.
27. Fox LP, Geyer AS, Husain S, Della-Latta P, Grossman ME. Mycobacterium abscessus cellulitis and multifocal abscesses of the breasts in a transsexual from illicit intramammary injections of silicone. J Am Acad Dermatol 2004;50:450-454.
28. Cuéllar ML, Scopelitis E, Tenenbaum SA, Garry RF, Silveira LH, Cabrera G, Espinoza LR. Serum antinuclear antibodies in women with silicone breast implants. J Rheumatol 1995;22:236-240.
29. Sanz-Herrero F, de Casimiro-Calabuig E, López-Miguel P. [Acute pneumonitis after subcutaneous injection of liquid silicone as a breast implant in a male-to-female transsexual]. Arch Bronconeumol 2006;42:205-206.
30. Clark RF, Cantrell FL, Pacal A, Chen W, Betten DP. Subcutaneous silicone injection leading to multi-system organ failure. Clin Toxicol (Phila) 2008;46:834-837.
31. Hage JJ, Kanhai RC, Oen AL, van Diest PJ, Karim RB. The devastating outcome of massive subcutaneous injection of highly viscous fluids in male-to-female transsexuals. Plast Reconstr Surg 2001;107:734-741.
32. Asscheman H, Gooren LJ. Hormone treatment in transsexuals. J Psychol Human Sex 1993;5:33-47.
33. Maycock LB, Kennedy HP. Breast care in the transgender individual. J Midwifery Womens Health 2013; doi:10.1111/jmwh.12066. [Epub ahead of print].
34. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003;59:409-418.
35. Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, De Cuypere G, Feldman J, Fraser L, Green J, Knudson G, Meyer WJ, Monstrey S, Adler RK, Brown GR, Devor AH, Ehrbar R, Ettner R, Eyler E, Garofalo R, Karasic DH, Lev AI, Mayer G, Meyer-Bahlburg H, Hall BP, Pfaefflin F, Rachlin K, Robinson B, Schechter LS, Tangpricha V, van Trotsenburg M, Vitale A, Winter S, Whittle S, Wylie KR, Zucker K. Standards of care for the health of transsexual, transgender, and gender nonconforming people. Int J Transgenderism 2011;13:165-232.
36. Ando S, De Amicis F, Rago V, Carpino A, Maggioloini M, Panno M, Lanzino M. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-125.
37. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113-120.
38. Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 1999;140:416-421.
39. Jayo MJ, Register TC, Hughes CL, Blas-Machado U, Sulistiawati E, Borgerink H, Johnson CS. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig 2000;7:257-265.
40. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725-1730.
41. Dimitrakakis C, Zhou J, Wang J, Belanger A, Labrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-298.
42. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PHM, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang Claude J, Clavel Chapelon F, Fournier A, Thibaut A, Gonzlez CA, Quirs JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071-1082.
43. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer risk: long-term results of a prospective study. Br J Cancer 2004;90:153-159.
44. Farhat G, Cummings S, Chlebowski R, Parimi N, Cauley J, Rohan T, Huang A, Vitolins M, Hubbell FA, Manson J, Cochrane B, Lane D, Lee J. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011;103:562-570.
45. Key T. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 2011;76:812-815.
46. Luthy IA, Begin DJ, Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988;31:845-852.
47. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72:2176-2182.
48. Saenger P. Management of Turner syndrome (gonadal dysgenesis). In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate; 2012.
49. Futterweit W. Endocrine management of transsexual. N Y State J Med 1980;80:1260-1264.
50. Prior JC. Hormonal therapy of gender dysphoria: The male-to-female transsexual. In: Denny D, ed. Concepts in Transgender Identity. New York: Garland Publishing Inc; 1998.
51. Basson RJ. Towards optimal hormonal treatment of male to female gender identity disorder. J Sex Reprod Med 2001;1:45-51.
52. Dahl M, Feldman J, Goldberg J, Jaberi A. Physical aspects of transgender endocrine therapy. Int J Transgenderism 2006;9:111-134.
53. Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol 2001;145:365-376.
54. Stanczyk F, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171-208.
55. Couse JF, Korach KS. Estrogen receptor null mice; what have we learned and where will they lead us? Endocr Rev 1999;20:358-417.
56. Lydon JP, Demayo FJ, Funck CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptors exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-2278.
57. Bondy CA. Turner Syndrome Study Group: care of girls and women with Turner syndrome: a guideline of the Turner syndrome study Group. J Clin Endocrinol Metab 2007;92:10-25.
58. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002;7:49-66.
59. Brisken C, Park S, Vass T, Lydon J, O'Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A 1998;95:5076-5081.
60. Longacre TA, Bartow SA. A correlative morphological study of human breasts and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-393.
61. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37.
62. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormonal therapy. Maturitas 2002;41:171-175.